Literature DB >> 16376512

A novel splicing mutation of the ATRX gene in ATR-X syndrome.

Takahito Wada1, Masae Sakakibara, Yoshimitsu Fukushima, Shinji Saitoh.   

Abstract

X-linked alpha-thalassemia/mental retardation syndrome (ATR-X, MIM#301040) is an X-linked recessive condition affecting males. ATR-X is characterized by severe mental retardation, mild HbH disease, dysmorphic facies, and genital and skeletal abnormalities. ATR-X is caused by mutations in the ATRX gene. Most mutations affect two functionally important domains, the ADD domain and the helicase domain. Here, we report on two brothers with the ATR-X phenotype without HbH disease; both had a mutation in the 5' upstream region of the ADD domain of the ATRX gene. This mutation was a G to T nucleotide substitution at the 3' end of exon 5 and resulted in splicing out of exons 5 and 6. Analysis of cDNA structure may clarify genotype-phenotype correlations in ATR-X because splicing mutation could be detectable only by cDNA analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16376512     DOI: 10.1016/j.braindev.2005.09.005

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

1.  Molecular mechanisms leading to null-protein product from retinoschisin (RS1) signal-sequence mutants in X-linked retinoschisis (XLRS) disease.

Authors:  Camasamudram Vijayasarathy; Ruifang Sui; Yong Zeng; Guoxing Yang; Fei Xu; Rafael C Caruso; Richard A Lewis; Lucia Ziccardi; Paul A Sieving
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

2.  The first case of X-linked Alpha-thalassemia/mental retardation (ATR-X) syndrome in Korea.

Authors:  Ki Wook Yun; Soo Ahn Chae; Jung Ju Lee; Sin Weon Yun; Byoung Hoon Yoo; In Seok Lim; Eung Sang Choi; Mi-Kyung Lee
Journal:  J Korean Med Sci       Date:  2010-12-22       Impact factor: 2.153

3.  Identification of a Hemizygous Novel Splicing Variant in ATRX Gene: A Case Report and Literature Review.

Authors:  Yan Cong; Jie Wu; Hao Wang; Ke Wu; Cui Huang; Xuejian Yang
Journal:  Front Pediatr       Date:  2022-04-04       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.